Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

Cancer Cell. 2002 Jun;1(5):413-5. doi: 10.1016/s1535-6108(02)00080-6.

Abstract

Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small molecule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Acute Disease
  • Antineoplastic Agents / pharmacology*
  • Benzamides
  • Enzyme Inhibitors / pharmacology*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myeloid / drug therapy*
  • Piperazines / pharmacology
  • Proto-Oncogene Proteins / antagonists & inhibitors*
  • Pyrimidines / pharmacology
  • Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Receptors, Cell Surface / antagonists & inhibitors*
  • fms-Like Tyrosine Kinase 3

Substances

  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Proto-Oncogene Proteins
  • Pyrimidines
  • Receptors, Cell Surface
  • Imatinib Mesylate
  • FLT3 protein, human
  • Receptor Protein-Tyrosine Kinases
  • fms-Like Tyrosine Kinase 3